Form 4: Cingulate EVP & CSO Receives Stock Option Grant

Cingulate Inc.'s EVP and CSO, Raul R. Silva, was granted 6,625 stock options with an exercise price of $4.34, effective December 31, 2025.

Summary

• Raul R. Silva, Executive Vice President and Chief Scientific Officer (EVP and CSO) of Cingulate Inc. (CING), was granted 6,625 stock options.
• The stock options have an exercise price of $4.34 per share.
• The transaction date for this grant was December 31, 2025.
• The options became exercisable on December 31, 2025, and will expire on December 31, 2036.
• The grant was made pursuant to the terms of Dr. Silva's Employment Agreement, as amended.
• Following this transaction, Dr. Silva beneficially owns 6,625 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of executive incentives with shareholder interests through a standard compensation practice. It does not contain any negative operational or financial news.

Positives

• The grant of stock options aligns the executive's financial interests with the long-term performance and shareholder value creation of Cingulate Inc.
• It represents a standard component of executive compensation, indicating a commitment to retaining key management personnel.

Future Outlook

The long expiration date of December 31, 2036, for the stock options suggests a long-term incentive for the EVP and CSO, aligning their future performance with the company's sustained growth and shareholder value over more than a decade.

Management Comments

• The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Industry Context

Stock options are a common tool in the pharmaceutical and biotechnology industry to attract and retain executive talent, particularly for roles like Chief Scientific Officer, which are critical for long-term research and development success. These grants incentivize executives to drive innovation and achieve strategic milestones, aligning their compensation with the company's growth trajectory.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across industries, particularly in growth-oriented sectors like biotechnology, to align executive incentives with shareholder value creation over the long term.
• The specific terms of the grant, such as the exercise price and expiration date, are typical for long-term incentive plans designed to retain key personnel and motivate performance over several years.

Corporate Governance

Related Party Transactions

• The grant of stock options to Raul R. Silva, an executive officer, constitutes a related party transaction, disclosed in accordance with SEC regulations.

Stakeholder Impact

• Shareholders: Potential positive impact due to enhanced alignment of executive incentives with long-term company performance and shareholder value creation.

Next Steps

• Dr. Silva may choose to exercise these options at any point between the exercisable date and the expiration date, subject to the terms of the option agreement.

Key Dates

Recommendation

This Form 4 details a routine executive compensation event—the grant of stock options to the EVP and CSO. Such grants are standard practice to align executive incentives with long-term shareholder value and do not typically signal a change in the company's fundamental outlook or warrant an immediate adjustment to an investment recommendation. Investors should continue to monitor the company's operational and financial performance.

Keywords

Cingulate Inc., CING, stock option, executive compensation, insider transaction, Form 4, Raul R. Silva, corporate governance